Catestatin (CgA352-372): Chromogranin A-Derived Anti-Adrenergic Peptide in Hypertension and Cardiometabolic Research

# Catestatin (CgA352-372): Chromogranin A-Derived Anti-Adrenergic Peptide in Hypertension and Cardiometabolic Research

Catestatin is a 21-amino acid peptide fragment derived from chromogranin A (CHGA), the prototypical granin protein co-stored with catecholamines in adrenal chromaffin cells and sympathetic nerve terminals. Discovered in 1997 as a potent endogenous inhibitor of nicotine-evoked catecholamine secretion, catestatin (CgA352-372, bovine numbering; CgA344-364 in human) represents a paradigmatic example of a regulatory peptide derived from a pro-hormone that exerts negative feedback on its own secretion. Its biology spans cardiovascular regulation, antimicrobial host defense, glucose metabolism, and adipose tissue function, making it one of the most pleiotropic chromogranin-derived peptides known.

Discovery and the Chromogranin A System

Chromogranin A was originally identified in 1965 as the major soluble protein of bovine adrenal medulla chromaffin granules by Banks and Helle. For three decades it was known primarily as a marker of neuroendocrine differentiation and a precursor for smaller bioactive peptides, but the specific functional identity of individual fragments remained elusive. The CHGA gene (chromosome 14q32.12 in humans) encodes a 457-amino acid precursor protein that undergoes extensive proteolytic processing to generate at least eight known bioactive peptides, including vasostatin-1 (CgA1-76), vasostatin-2 (CgA1-113), chromofungin, pancreastatin (CgA250-301), parastatin, catestatins, serpinin, and WE-14.

Catestatin was isolated and characterized in 1997 by Mahata et al. working at the University of California San Diego in the laboratory of Daniel O'Connor. The team was searching for endogenous regulators of catecholamine secretion from bovine adrenal chromaffin cells. Using biochemical fractionation of chromaffin granule content proteins, they identified a peptide corresponding to residues 352-372 of bovine chromogranin A (RSMRLSFRARGYGFRGPGLQL) that potently inhibited nicotine-stimulated catecholamine release at nanomolar concentrations. They named the peptide "catestatin" (catecholamine-release-inhibiting peptide), and the original characterization appeared in Nature (1997, volume 389, pages 272-276). This paper established catestatin as the first identified endogenous non-opioid inhibitor of catecholamine secretion and as a direct negative feedback regulator of sympathoadrenal activity.

The human catestatin sequence (CgA344-364: SSMKLSFRARAYGFRGPGLQL) differs from bovine catestatin at four positions (R344S, M354A, R356A, and L365L — positions shifted due to species alignment differences), and these substitutions significantly affect potency. Bovine catestatin inhibits nicotine-evoked catecholamine release with an IC₅₀ of approximately 130 nM, while the human sequence shows somewhat lower potency in chromaffin cell bioassays (IC₅₀ ~500 nM). Several naturally occurring human single nucleotide polymorphisms (SNPs) in the catestatin sequence have been identified that further alter biological activity, most notably the P370L variant (CgA364L) associated with hypertension in multiple populations.

Molecular Structure and Receptor Pharmacology

Catestatin is a 21-amino acid cationic amphipathic peptide. The human sequence (SSMKLSFRARAYGFRGPGLQL) has a calculated molecular weight of approximately 2,340 Da and a net positive charge of +2 at physiological pH (due to arginine residues at positions 9 and 11, and lysine at position 4). The peptide adopts an α-helical secondary structure in membrane-mimetic environments, which is relevant to both its receptor interactions and its membrane-disruptive antimicrobial activity.

The primary characterized receptor mechanism involves non-competitive antagonism of the nicotinic acetylcholine receptor (nAChR) at sympathetic nerve terminals and adrenal chromaffin cells. Catestatin interacts with both α3β4 and α3β2 nAChR subtypes (the dominant subtypes in sympathoadrenal tissue) and inhibits nicotine-evoked ion currents with IC₅₀ values in the 100-600 nM range depending on the specific subunit composition. The antagonism mechanism appears to involve channel block rather than competitive displacement of acetylcholine, consistent with a pore-blocking mechanism. This nicotinic antagonism explains the inhibition of catecholamine release, since nicotinic receptor activation is the primary mechanism by which preganglionic splanchnic nerve stimulation triggers chromaffin cell secretion.

Beyond nicotinic receptors, catestatin has been shown to interact with additional molecular targets:

FPR2/FPRL1 (Formyl Peptide Receptor 2): Yang et al. (2019, PMID: 31085171) demonstrated that some anti-inflammatory effects of catestatin are mediated through FPR2, a pattern recognition receptor involved in resolution of inflammation. Catestatin activates FPR2 at concentrations achievable under physiological conditions, triggering calcium mobilization and downstream anti-inflammatory signaling pathways including ERK1/2 and PI3K/Akt.

Neuropilin-1: Recent structural studies suggest catestatin may interact with neuropilin-1 (NRP1), a co-receptor for VEGF and semaphorins, potentially contributing to its effects on angiogenesis and wound healing.

Direct membrane interactions: At higher concentrations (>1 μM), catestatin disrupts bacterial membranes via charge-mediated electrostatic interaction followed by membrane insertion of the hydrophobic face, which underlies its antimicrobial activity.

Tissue Distribution and Biosynthesis

Chromogranin A, the catestatin precursor, is expressed in virtually all neuroendocrine cells, making catestatin generation theoretically possible throughout the neuroendocrine system. The highest expression of CHGA occurs in adrenal chromaffin cells, where catestatin-generating processing is well-documented. Additional major sites include:

• •Sympathetic nerve terminals (where CgA co-release with norepinephrine has been demonstrated)
• •Adrenergic and dopaminergic neurons of the central nervous system
• •Enterochromaffin and enterochromaffin-like cells of the gastrointestinal tract
• •D cells and EC cells of pancreatic islets
• •Thyroid C cells (calcitonin-secreting)
• •Pituitary corticotrophs and other pituitary cell types
• •Parathyroid chief cells

The proteolytic processing of chromogranin A to generate catestatin involves prohormone convertases (primarily PC1/PC3 and PC2) acting at paired basic residue sites (KR, RR) flanking the catestatin sequence. Furin and kallikrein have also been implicated in catestatin generation at different tissue sites. The efficiency of processing and the exact catestatin variants generated can differ substantially between tissues, creating a complex landscape of circulating catestatin isoforms.

Plasma catestatin concentrations in healthy humans have been measured at approximately 1-4 nM by radioimmunoassay, with significant individual variation. These circulating concentrations are at the threshold for biological activity, suggesting that local concentrations in the synaptic cleft or paracrine environment may substantially exceed plasma levels and achieve stronger biological effects.

Cardiovascular Regulation

The cardiovascular biology of catestatin has been extensively studied, particularly in the context of hypertension where plasma catestatin is a potential biomarker and therapeutic target.

Anti-Hypertensive and Vasodilatory Effects

Catestatin produces vasodilation through at least two distinct mechanisms:

Indirect sympathoinhibition: By blocking nicotinic receptor-mediated catecholamine release from sympathetic nerve terminals and the adrenal medulla, catestatin reduces circulating and tissue norepinephrine/epinephrine levels, thereby attenuating sympathetically mediated vasoconstriction.

Direct endothelium-dependent vasodilation: Kennedy et al. (2011,) demonstrated that catestatin induces nitric oxide (NO) production from vascular endothelium via a histamine H1 receptor-dependent pathway and subsequent activation of endothelial NO synthase (eNOS). This vasodilatory effect is partially blocked by antihistamines and completely abolished by L-NAME (NOS inhibitor), confirming NO dependence.

Mast cell histamine release: Catestatin acts as a mast cell secretagogue, releasing histamine from mast cells, which then activates endothelial H1 receptors to trigger NO production. This indirect mechanism couples catestatin to endothelial vasodilation.

Intravenous administration of catestatin in anesthetized rats produces dose-dependent reductions in mean arterial pressure and total peripheral resistance, with a hypotensive dose range of 0.1-10 nmol/kg.

Catestatin Deficiency in Hypertension

A critical finding from multiple independent studies is that plasma catestatin levels are significantly reduced in hypertensive patients compared to normotensive controls. Mahata et al. (2003,) first reported this inverse relationship, and subsequent studies in different populations have confirmed it. The degree of catestatin reduction correlates with blood pressure elevation, and importantly, first-degree normotensive relatives of hypertensive patients also show intermediate catestatin levels, suggesting a genetic component.

Genome-wide association studies and targeted sequencing of the CHGA gene have identified several variants that influence catestatin levels or activity:

• •P370L (human CgA364L): This SNP results in a proline-to-leucine substitution within the catestatin sequence itself. The Leu370 variant shows reduced inhibitory potency toward nicotinic receptors compared to the wild-type Pro370 peptide. Carriers of the 370L allele have higher blood pressure in some population studies.
• •CHGA promoter variants: SNPs in the CHGA promoter region affect overall chromogranin A expression and thus catestatin availability.
• •Processing site variants: SNPs at the flanking dibasic cleavage sites (upstream KR or RR motifs) alter proteolytic processing efficiency.

Mice with targeted deletion of the CHGA gene (Chga−/− mice) develop hypertension and increased plasma catecholamine levels, directly demonstrating the blood pressure regulatory role of chromogranin A-derived peptides. Reconstitution of these mice with either the bovine or human catestatin sequence (via osmotic pump delivery) partially rescues the hypertensive phenotype, confirming catestatin as a key anti-hypertensive chromogranin A fragment.

Cardiac Effects

Beyond vascular tone regulation, catestatin exerts direct and indirect effects on cardiac function:

Negative inotropic effects: Catestatin decreases cardiac contractility in isolated heart preparations, with an EC₅₀ for negative inotropy in the high nanomolar range. This effect is mediated partly by reduction of catecholamine release at cardiac sympathetic terminals (nicotinic antagonism) and partly by direct cardiomyocyte effects involving cGMP-dependent pathways.

Cardioprotective effects against ischemia-reperfusion injury: Angelone et al. (2008, PMID: 18003822) demonstrated that catestatin pretreatment reduces infarct size in isolated perfused rat hearts subjected to ischemia-reperfusion. The protective mechanism involves activation of a reperfusion injury salvage kinase (RISK) pathway, including PI3K/Akt and ERK1/2 phosphorylation, and reduced mitochondrial permeability transition pore (mPTP) opening.

Heart failure biomarker: Multiple clinical studies have found plasma catestatin to be significantly reduced in patients with chronic heart failure (CHF) compared to healthy controls. Lower catestatin levels correlate with higher B-type natriuretic peptide (BNP), reduced ejection fraction, and worse functional class. Rosjo et al. (2010,) demonstrated that catestatin is an independent predictor of cardiovascular mortality in CHF patients, with lower catestatin quartiles showing significantly higher mortality rates.

Antimicrobial Activity

Catestatin displays broad-spectrum antimicrobial activity against a range of pathogens, an activity first described by Briolat et al. (2005,) and subsequently expanded by multiple groups.

The antimicrobial mechanism involves:

1. Electrostatic attraction of the cationic catestatin peptide to negatively charged bacterial membranes (LPS for Gram-negative, teichoic acids for Gram-positive)

2. Insertion of the amphipathic α-helix into the membrane bilayer

3. Membrane permeabilization leading to ion leakage and cell death

Minimum inhibitory concentrations (MICs) against common pathogens range from 1-10 μg/mL for Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Candida albicans — within the range of endogenous defensins. Catestatin also shows activity against drug-resistant strains including methicillin-resistant S. aureus (MRSA), making it of potential interest for anti-infective drug development.

The antimicrobial and immunomodulatory properties of catestatin are relevant in the skin barrier, where chromogranin A is expressed in keratinocytes and contributes to host defense. Chromogranin A processing in skin generates both catestatin and vasostatin, both of which contribute to the cutaneous antimicrobial peptide repertoire.

Metabolic Functions

Glucose Homeostasis and Insulin Sensitivity

Chromogranin A and its derived peptides have documented roles in pancreatic islet function. Catestatin exerts complex effects on glucose-stimulated insulin secretion (GSIS):

In isolated pancreatic β-cells and perfused pancreas preparations, catestatin at concentrations of 10-100 nM modestly enhances GSIS through mechanisms that remain incompletely characterized. This is in contrast to pancreastatin (CgA250-301), another CHGA-derived peptide that potently inhibits GSIS via Gαi signaling. The net effect of chromogranin A processing in the islet thus depends on which fragment predominates under specific physiological conditions.

In the context of insulin resistance, circulating catestatin levels are reduced in subjects with type 2 diabetes mellitus (T2DM) compared to normoglycemic controls, consistent with the pattern seen in hypertension. Rao et al. (2013) showed that catestatin concentrations inversely correlate with homeostatic model assessment of insulin resistance (HOMA-IR) and fasting insulin levels, independent of body mass index. Whether this reduction represents a cause or consequence of insulin resistance remains under investigation.

Adipose Tissue Regulation

Chromogranin A is expressed in mature adipocytes and preadipocytes, and catestatin has been shown to directly affect adipocyte biology. Bandyopadhyay et al. (2015,) demonstrated that:

• •Catestatin promotes adipogenesis from preadipocytes via activation of a cAMP/PKA/PPARγ pathway
• •Catestatin enhances lipid uptake and storage in differentiated adipocytes
• •Catestatin suppresses lipolysis, particularly β-adrenergic stimulated lipolysis (consistent with its anti-adrenergic mechanism)
• •Catestatin knockout (Chga−/−) mice show altered adipose tissue morphology and reduced fat mass under high-fat diet conditions

This adipose biology positions catestatin as a paracrine/autocrine regulator of energy storage, creating feedback between adrenergic tone and adipocyte lipid dynamics.

Anti-Inflammatory Properties

Beyond its cardiovascular and metabolic roles, catestatin functions as an endogenous immunomodulatory agent:

Macrophage polarization: Catestatin promotes an M2 anti-inflammatory macrophage phenotype. Treatment of LPS-stimulated macrophages with catestatin (at 100-500 nM) suppresses NF-κB activation, reduces IL-6, TNF-α, and IL-1β production, and enhances anti-inflammatory IL-10 secretion.

Mast cell regulation: While catestatin stimulates initial histamine release from mast cells (contributing to vasodilation), it subsequently acts as a brake on mast cell activation by promoting desensitization.

Resolution of inflammation: Through FPR2 activation (a receptor also engaged by lipoxin A4 and annexin-1 in pro-resolution pathways), catestatin actively promotes resolution of acute inflammation rather than simply inhibiting inflammatory initiation.

This anti-inflammatory activity is relevant to cardiovascular protection, where low-grade inflammation is a key driver of atherosclerosis and cardiac remodeling in heart failure.

Research Tools and Experimental Systems

Clinical Correlates and Translational Potential

Catestatin as a Cardiovascular Biomarker

The consistent finding of reduced plasma catestatin across multiple cardiometabolic conditions — hypertension, heart failure, T2DM, metabolic syndrome — has generated interest in catestatin as a diagnostic or prognostic biomarker. Key clinical observations include:

• •Plasma catestatin independently predicts major adverse cardiovascular events (MACE) in post-myocardial infarction cohorts
• •Catestatin levels inversely correlate with left ventricular mass index in hypertensive patients, suggesting a relationship to hypertensive target organ damage
• •Catestatin is reduced in the first trimester of pregnancies that later develop preeclampsia, positioning it alongside other early preeclampsia biomarkers
• •In the FINRISK cohort, lower catestatin tertiles associated with increased cardiovascular mortality over 10-year follow-up

However, catestatin measurement has not yet been standardized across clinical laboratories, and reference ranges depend on the specific antibody and assay format used. Assay development for high-sensitivity catestatin measurement comparable to established cardiac biomarkers remains an active area.

Therapeutic Approaches

Several strategies have been explored to harness catestatin biology therapeutically:

Exogenous catestatin administration: Proof-of-concept studies in rodent models of hypertension (spontaneously hypertensive rats, DOCA-salt hypertension) and heart failure demonstrate blood pressure reduction and cardiac protection with catestatin infusion. The short plasma half-life (estimated 5-15 minutes in vivo due to proteolytic degradation) represents a delivery challenge for therapeutic development.

Stabilized analogs: Several groups have synthesized catestatin analogs with improved stability through backbone methylation, D-amino acid substitution, or peptidomimetic approaches. An analog designated catestatin-H5 (incorporating helix-stabilizing modifications) showed improved half-life and maintained vasodilatory activity in preliminary studies.

CHGA gene therapy: Adeno-associated virus (AAV) delivery of CHGA constructs to adrenal glands has been explored in Chga−/− mice as a proof of concept for restoring catestatin production, but this approach remains far from clinical application.

Small molecule FPR2 agonists: Given catestatin's FPR2-mediated anti-inflammatory effects, FPR2 agonists developed for other indications (such as resolvin analogs) may recapitulate some catestatin biological effects.

Current Research Frontiers

Several unresolved questions drive active investigation in catestatin biology:

Receptor identity for all effects: While nicotinic receptors and FPR2 account for some catestatin actions, a high-affinity dedicated catestatin receptor mediating vasodilatory and cardiac effects has not been definitively identified. The possibility of an as-yet uncharacterized receptor remains open.

Catestatin isoforms: Proteolytic processing of CgA generates multiple catestatin-related fragments of different lengths. The relative potency and receptor selectivity of these isoforms (e.g., extended catestatin including additional N- or C-terminal residues) is incompletely characterized.

Gut microbiome connections: The gut neuroendocrine system expresses CHGA, and emerging data suggest catestatin may influence gut microbiota composition. Conversely, microbial proteases may generate catestatin-like fragments from luminal chromogranin A, creating a bidirectional connection.

Aging and catestatin decline: Plasma catestatin levels appear to decline with age in some longitudinal studies, potentially contributing to age-associated increases in sympathetic tone and blood pressure. Whether catestatin supplementation could attenuate age-related sympathoadrenal overactivity is an unexplored research avenue.

Integration with other chromogranin A-derived peptides: CgA generates multiple bioactive fragments simultaneously, and the balance between vasostatin (vasodilatory, N-terminal), catestatin (anti-adrenergic, mid-region), and pancreastatin (pro-diabetic, C-terminal) determines the net physiological output. Understanding how processing enzyme expression and activity regulate this balance is an emerging research priority.

Conclusion

Catestatin exemplifies a new class of cardiovascular regulatory peptide: a fragment derived from a granin co-stored with the very transmitters it inhibits, creating an elegant negative feedback circuit on sympathoadrenal activity. Its discovery resolved a decades-long question about how catecholamine secretion is restrained between sympathetic nerve impulses, and its subsequent characterization as a vasodilator, cardioprotective agent, antimicrobial peptide, and adipokine revealed unexpectedly broad biological relevance. The consistent association of reduced catestatin with hypertension, heart failure, type 2 diabetes, and metabolic syndrome positions it as both a window into the pathophysiology of sympathoadrenal excess and a potential therapeutic target. Research-grade human catestatin peptide (CgA344-364) and the bovine sequence (CgA352-372) are available from multiple suppliers and are the standard tools for in vitro pharmacology; the Chga−/− mouse is the primary in vivo model for catestatin deficiency phenotyping. Translating catestatin biology toward clinical utility will require addressing its short half-life and developing reliable plasma assays for stratifying cardiovascular risk.

Key References

2. Mahata SK, Mahata M, Wen G, et al. Catestatin: A multifunctional peptide from chromogranin A. Regul Pept. 2010;162(1-3):33-43. PMID: 20347877

4. Angelone T, Quintieri AM, Brar BK, et al. The antihypertensive chromogranin A-derived peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac function. Endocrinology. 2008;149(9):4780-4793. PMID: 18003822

5. Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem. 1999;274(5):2920-2928. PMID: 9915832

9. Yang D, Chen Q, Shi J, et al. Catestatin activates the formyl peptide receptor 2 and induces inflammation resolution. FASEB J. 2019;33(7):8228-8240. PMID: 31085171

---

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. Catestatin and related chromogranin A-derived peptides are not approved therapeutic agents. All research applications must comply with applicable institutional, local, and national regulations.